Reckitt, maker of Mucinex and Lysol, expands US output with $400 million
Subscribe to our free newsletter today to keep up to date with the latest renewable energy news.
For decades, the prevailing logic behind global manufacturing was relatively straightforward: companies placed factories where production costs were attractive, developed international supplier networks and relied on logistics operations to bridge the distance between factories and consumers. Reckitt is now working from a different calculation, one that places greater value on responsiveness, proximity and the ability to adapt production when demand changes unexpectedly.
The British consumer health and hygiene company, whose brands include Mucinex and Lysol, is investing another $400 million in its US operations over the next four years, building on a $200 million commitment announced in 2024 and taking its planned US investment to as much as $600 million.
A substantial share of that spending will support the expansion of a manufacturing facility in Wilson, North Carolina, which Reckitt acquired in 2024 and is developing into its largest US over-the-counter manufacturing site. The company plans to add 234000 square feet to the facility, which is expected to open in the first half of 2027 and eventually manufacture more than 80% of the Mucinex products Reckitt sells in the US.
The investment can easily be viewed as another example of reshoring, particularly as manufacturers continue to reconsider the risks associated with long and geographically dispersed supply chains. The more significant operational story, however, lies in Reckitt’s effort to reduce the physical and organizational distance between a volatile consumer market and the factories responsible for supplying it.
Shorter supply chains can turn response time into an operating advantage
Cold and flu medicine creates an unusually difficult forecasting problem because demand can rise quickly when illness spreads, yet the timing, severity and geographic concentration of a seasonal outbreak are difficult to predict months in advance. Manufacturers must therefore maintain enough capacity and inventory to meet a sudden increase in demand without committing so much stock that unsold products accumulate if the season turns out to be relatively mild.
That uncertainty gives production lead time a much greater commercial importance than it carries in categories where purchasing patterns are more stable and predictable. A factory located closer to its primary customer base can respond more quickly when retailers need additional stock, allowing planners to react to actual sales rather than relying almost entirely on forecasts produced several months earlier.
Reckitt’s Wilson investment was first announced in December 2024, when the company said it would spend $200 million to establish the North Carolina operation and create nearly 300 jobs. The facility was designed to manufacture Mucinex tablets and liquids for the US market, reducing Reckitt’s dependence on production located farther from its American customers.
The latest commitment expands that strategy by adding manufacturing capacity for Mucinex while increasing production volumes for the company’s Move Free brand. Reckitt also plans to give the enlarged facility room for additional capabilities in the future, creating a manufacturing base that can adapt as product demand, portfolio priorities and market conditions change.
The commercial value of that flexibility becomes clearer when seasonal demand weakens or arrives at a different time than expected. Reckitt reported that its North American self-care business declined at a mid-single-digit rate during the first half of 2025, with inventory levels, the timing of the cold and flu season and a planned Mucinex reformulation among the factors affecting performance.
Manufacturers have traditionally evaluated offshore production decisions heavily against labor, raw material and factory costs, but localization introduces another variable that can be harder to capture in a procurement comparison: the financial value of time. A factory closer to its end market can reduce some transportation exposure, shorten replenishment cycles and give planners more opportunity to correct inventory positions when real demand begins to diverge from the forecast.
Recent reshoring research suggests that manufacturers are assigning greater weight to those factors when evaluating domestic production. In the 2026 USA Reshoring Survey, 70% of OEM respondents that reported benefits from reshoring cited improved speed to market, while 65% reported better fulfillment or on-time delivery and 60% cited logistics savings.
Those findings come from a survey of 249 manufacturers rather than the entire US industrial base, so they should not be interpreted as representative of every manufacturing sector. They do, however, indicate that the business case for domestic production is increasingly being evaluated through a broader measure of operating performance rather than factory cost alone.
Reckitt is shortening the distance between R&D and production
Manufacturing represents only one part of Reckitt’s US investment strategy because the company is also consolidating commercial and research operations at a campus in Nutley, New Jersey, while developing a science and innovation center focused on germ protection products, including Lysol. Reckitt says the structure is intended to bring scientific research, consumer insight and commercial execution closer together so new products can move more efficiently from development into the market.
That connection matters because reducing transportation time after a product leaves a factory provides only part of the potential advantage available from a more localized operating model. Companies can gain additional speed when research teams, commercial decision-makers and manufacturing operations are structured to respond to the same market signals without lengthy handoffs between regions, departments or production networks.
The model brings together several functions that large manufacturers have often managed as separate parts of the organization, even though delays in one can affect the performance of all the others. Consumer demand informs product decisions, research and development turns those decisions into viable products, manufacturing converts those products into volume and distribution moves finished goods into stores and ecommerce channels.
Reducing the delay between those stages can have as much operational significance as cutting transit time once a product has entered the logistics network, particularly when a company is competing in categories where demand can change quickly. Faster communication between commercial teams and factories can help production planning respond to sales patterns sooner, while closer links between R&D and manufacturing can reduce friction when a new product needs to move from development into scaled production.
Mucinex provides a useful illustration of the connection between product development and manufacturing capacity. In August 2026, Reckitt announced FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, which the company described as the first FDA-approved OTC innovation in the cold and flu category in 14 years.
The product combines three active ingredients in a bi-layer tablet designed to provide up to 12 hours of symptom relief, and Reckitt said it followed more than a decade of research, development, clinical evaluation and regulatory work. The company is now increasing domestic manufacturing capacity at a time when it is also introducing new products into the category, linking innovation more closely with the physical ability to produce additional volume.
Viewed together, the investments in research, commercial operations and manufacturing suggest that Reckitt wants to shorten the full path between identifying a consumer need and supplying a finished product at scale. For operations executives, that broader system may be more instructive than the factory expansion considered on its own because it shows how localization can extend beyond the manufacturing floor.
Reshoring is becoming a question of total operating performance
US reshoring has often been discussed through the narrow lenses of geopolitical risk, tariffs, industrial policy and supply security, but manufacturers increasingly appear to be weighing a wider collection of operational considerations when they decide where future production should sit.
The 2026 USA Reshoring Survey found that 36% of participating OEMs had reshored or were actively undertaking additional reshoring, compared with 29% in the previous survey, while 63% said they planned US capital spending in 2026 or 2027 to support reshoring or other domestic expansion.
The same research also shows why the economics remain difficult for manufacturers that are considering moving more production back to the US. Among contract manufacturers surveyed, 94% said price was the main reason they lost orders to imports, while workforce availability remained another constraint, with 66% of respondents describing recruitment for technicians such as machinists, welders and electrical or chemical technicians as very difficult or at crisis levels.
Domestic production therefore does not automatically represent the cheaper or simpler option, particularly in categories where overseas suppliers offer substantial labor-cost advantages, established supplier ecosystems or specialized production capabilities. The calculation becomes more complicated when companies begin measuring the cost of inventory, freight, long replenishment cycles, unexpected disruption and the inability to react quickly when customer demand changes.
An offshore factory may still deliver a lower direct production cost while requiring longer lead times, larger safety stocks and greater exposure to transportation disruption. A domestic facility may carry higher operating costs but provide faster replenishment, closer coordination with commercial teams and greater flexibility when production plans need to change.
Reckitt’s investment puts a substantial financial commitment behind that broader calculation because its North Carolina facility is not simply another source of manufacturing capacity. The site is intended to place production closer to one of the company’s most important consumer markets while the company’s wider US investment brings manufacturing, product development and commercial decision-making into closer alignment.
For manufacturers reconsidering global supply networks, the most instructive figure may therefore be neither the additional $400 million nor the total $600 million Reckitt plans to invest. The more consequential measure is the amount of time that can be removed between detecting a change in demand, adjusting production and placing finished products in front of customers when they are ready to buy.
Source:
The Wall Street Journal
